The Biden administration is expected to release the next batch of drugs that will be subject to Medicare price negotiations — ...

In a recent episode of the global health and wellness show Bloom, host Gayle Guyardo welcomed Dr. Bharti Shetye, MD, MFOMA, a ...

Trump could keep Biden’s commitment to have Medicare pay for weight loss drugs such as Ozempic and Wegovy. But would ...

New tests may show how much value a particular obese patient will get for a GLP-1 agonist prescription dollar.

For the past two years, Ozempic and Wegovy have dominated the conversation when it comes to weight-loss medications (WLMs). The two medications, developed and distributed by Novo Nordisk, have made ...

Weight-loss drugs such as Ozempic and Wegovy are increasingly popular among adults, who have flocked to the new medications as alternatives to the traditional — and often ineffective — advice ...

Indiana’s Medicaid program estimates the Biden administration’s proposal to expand coverage of weight-loss treatment for ...

With 13 states offering coverage, it’s already a $3.9 billion cost. Some state officials say reducing obesity will save programs money in the long run.

The results of the first head-to-head trial of Lilly's dual GLP-1/GIP agonist Zepbound (tirzepatide) and Novo Nordisk's GLP-1 agonist Wegovy (semaglutide ... 25% body weight loss compared to ...

Holiday whiplash over CTA enforcement, Nvidia stock pops on CES keynote, weight loss drugs drive healthcare costs up.